Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.

Specimen suitability remains a major obstacle to clinical NGS testing. We determined that PCR-based library creation methods allow the use of smaller specimens, and those with a lower percentage of tumor cells to be run on the PCDx NGS platform.